Corticotropin releasing factor 2 receptor agonists

Details Corticotropin releasing factor 2 receptor agonists Corticotropin releasing factor 2 receptor agonists

2005-08-30

2005-08-30

Russel, Jeffrey Edwin (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S324000

Reexamination Certificate

active

06936585

ABSTRACT:
Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.

REFERENCES:
patent: 5235036 (1993-08-01), Kornreich et al.
patent: 5663292 (1997-09-01), Rivier
patent: 5786203 (1998-07-01), Lovenberg et al.
patent: 5824771 (1998-10-01), Rivier
patent: 5844074 (1998-12-01), Rivier
patent: 5869450 (1999-02-01), Wei et al.
patent: 6670140 (2003-12-01), Isfort et al.
patent: 0 860 501 (1998-08-01), None
patent: WO 96/37223 (1996-11-01), None
patent: WO 97/00063 (1997-01-01), None
Eckart, K. et al., “A single amino acid serves as an affinity switch between the receptor and the binding protein of corticotropin-releasing factor: implications for the design of agonists and antagonists”,Proceedings of the National Academy fo Sciences of the United States, 2001, vol. 98, No. 20, pp. 11142-11147.
Beyermann, M. et al., “A single-point slight alteration set as a tool for structure—activity relationship studies of ovine corticotropin releasing factor”,J. Medicinal Chemistry, 1996, vol. 39, No. 17, pp. 3324-3330.
Korneich, W.D. et al., “Alanine Series Of Ovine Corticotropin Releasing Factor (oCFR): A structure —Activity Relationship Study”,J. of Medicinal Chemistry, Amer. Chem. Society, 1992, vol. 35, No. 10, pp 1870-1876.
Ruhmann, A. et al., “Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): Development of CRFR2β-selective antisauvagine-30”,Proceedings of the National Academy of Sciences of the United States, 1998, vol. 95, No. 26, pp. 15264-15269.
Assil, I. Q. et al., “An Oxidation resistant radioligand for corticotropin-releasing factor receptors”,Peptides, 2001, vol. 22, No. 7, pp. 1055-1061.
T.M. Reyes, et al., “Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors”,PNAS, vol. 98, No. 5, pp. 2843-2848 (2001).
E.B De Souza, et al., “Corticotropin-Releasing Factor Receptors: Physiology, Pharmacology, Biochemistry and Role in Central Nervous System and Immune Disorders”,Psychoneuroendocrinology, Elsevier Science Ltd., USA , vol. 20, No. 8, pp. 789-819 (1995).
D.T. Chalmers, et al., “Corticotropin-releasing factor receptors: from molecular biology to drug design”,TiPS, Elsevier Science Ltd., USA , vol. 17, pp. 166-172, (1996).
H.A. Thomas, et al., “CRF and Related Peptides as Anti-Inflammatory Agonists”,Annals New York Academy of Sciences, pp. 219-228 (1993).
E.T. Wei, et al., “Peripheral anti-inflammatory actions of corticotropin-releasing factor”,Ciba Foundation Symposium 172, Wiley, Chichester , pp. 258-276, (1993).
J.R. McCarthy, et al., “Recent Advances with the CRF1Receptor: Design of Small Molecule Inhibitors, Receptor Subtypes and Clinical Indications”,Current Pharmaceutical Design, , Bentham Science Publishers B.V. vol. 5 pp. 289-315 (1999).
J.R. McCarthy, et al., “Chapter 2. Recent Progress in Corticotropin-Releasing Factor Receptor Agents”,Annual Reports in Medicinal Chemistry, Academic Press, vol. 34, pp. 11-20 (1999).
G.P. Chrousos, et al., “Corticotropin Releasing Factor: Basic Studies and Clinical Applications”,Prog. Neuro-Psychopharmacol.&Biol. Phychiat., Pergamon Press Ltd, Great Britain, vol. 9, pp. 349-359 (1985).
G. B. Cutler, Jr., M.D., “Corticotropin-Releasing Hormone (CRH): Clinical Studies and Use”,The Endocrinologist, Suppl. 1, Williams & Wilkins, vol. 7, No. 1, pp. 10S-16S (1997).
M.J. Owens, et al., “Physiology and Pharmacology of Corticotropin-releasing Factor”,Pharmacological Reviews, The American Society for Pharmacology and Experimental Therapeutics, USA. vol. 43, No. 4, pp. 425-473 (1991).
L. Arborelius, et al., “The role of corticotropin-releasing factor in depression and anxiety disorders”,Journal of Endocrinology, Society for Endocrinology, Great Britain, vol. 160, pp. 1-12 (1999).
D.N. Orth, “Corticotropin-Releasing Hormone in Humans”,Endocrine Reviews, The Endocrine Society, USA., vol. 13, No. 2, pp. 164-191 (1992).
E. Emeric-Sauval, “Corticotropin-Releasing Factor (CRF)—A Review”,Psychoneuroendocrinology, Pergamon Journals Ltd., Great Britain , vol. 11, No. 3, pp. 277-294 (1985).
J. Spiess, et al., “Molecular Properties of the CRF Receptor”,TEM, Elsevier Science Ltd., vol. 9, No. 4, pp. 140-145 (1998).
K.D. Dieterich, et al., “Corticotropin-releasing factor receptors: An overview”,Exp. Clin. Endocrinol. Diabetes, Johann Ambrosius Barth, vol. 105, pp. 65-82 (1997).
P.J. Gilligan, et al., “Corticotropin Releasing Factor (CRF) Receptor Modulators: Progress and Opportunities for New Therapeutic Agents”,Journal of Medicinal Chemistry, American Chemical Society, vol. 43, No. 9, pp. 1641-1660 (2000).
C.A. Maltin, et al., “Clenbuterol, a β-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients”,Clinical Science, vol. 84, pp. 651-654 (1993).
J.F. Signorile, et al., “Increased Muscle Strength in Paralyzed Patients after Spinal Cord Injury: Effect of Beta-2 Adrenergic Agonist”,Arch Phys Med Rehabil, vol. 76. pp. 55-58 (1995).
L. Martineau, et al., “Salbutamol, a β2-adrenoceptor agonist, increases skeletal muscle strength in young men”,Clinical Science, vol. 83. pp. 615-621 (1992).
M.H. Perrin, et al., “Diverse roles of corticotropin releasing factor receptors and their ligands”,Amer. Zoologist, vol. 40, No. 6, pp. 1168-1169 (2000).
O. Valdenaire,et al., “A new functional isoform of the human CFR2 receptor for corticotropin releasing factor”,Biochimica et Biophysica Acta, vol. 1352, pp. 129-132 (1997).
M.R Palchaudhuri,. et al., “Isolation and pharmacological characterization of two functional splice variants of corticotropin-releasing factor type 2 receptor from Tulpaia belangeri”,J. of Neuroendocrinology, vol. 11, pp. 419-428 (1999).
D.E. Grigoriadis, et al., “125I-Tyr0-Sauvagine: A novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor2areceptors”,Molecular Pharmacology, vol. 50, pp. 679-686 (1996).
N. Suman-Chauhan, et al., “Expression and characterisation of human and rat CRF2αreceptors”,Eur. J. Pharmacol., vol. 379, pp. 219-227 (1999).
T. Kishimoto, et al., “A sauvagine/ corticotropin-releasing factor receptor expressed in heart and skeletal muscle”,Proc. Natl. Acad. Sci. USA, vol. 92, pp. 1108-1112 (1995).
T. Bale, et al., “Mice Deficient for Both Corticotropin—Releasing Factor Receptor 1 (CRFR1) and CRFR2 Have an Impaired Stress Response and Display Sexually Dichotomous Anxiety—Like Behavior”,The Journal of Neuroscience, vol. 22, No. 1, pp. 193-199 (2002).
M. Perrin, et al., “ Corticotropin Releasing Factor Receptors and Their Ligand Family”,Annals New York Academy of Sciences, pp. 312-328, (not dated).
K. Lewis, et al., “Identification of urocortin III, an additional member of the corticotropin—releasing factor (CRF) family with high affinity for the CRF2 receptor”,PNAS, vol. 98, No. 13, pp. 7570-7575, (2001).
S. Hsu, et al., “Human stresscopin and stresscopin—related peptide are selective ligands for the type 2 corticotropin—releasing hormone receptor”,Nature Medicine, vol. 7, No. 5, pp. 611 (2001).
H. Appell, et al., “Muscular Atrophy Following Immobilisation A Review”,Sports Medicine, vol. 10, No. 1, pp. 42-58 (1990).
G. Smith, et al., “Corticotropin Releasing Factor Receptor 1—Deficient Mice Display Decreased Anxiety, Impaired Stress Response, and Aberrant Neuroendocrine Development”,Neuron, vol. 20

Affiliated with

Also associated with

Rating

Corticotropin releasing factor 2 receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Corticotropin releasing factor 2 receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Corticotropin releasing factor 2 receptor agonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3450797